Description: Recce Limited is an Australia-based research-based pharmaceutical company. The Company is principally engaged in research and development of antibiotic drugs and anticancer drugs. The Company's antibiotics kill both susceptible bacteria and drug resistant super bugs throughout the world health danger arising from resistance to present-day antibiotics. The Company offers antibiotic drugs to treat the diseases caused by Sepsis, Helicobacter Pylori (H.Pylori), Escherichia coli (E.coli), Gonorrhea and Tuberculosis (TB). The Company offers anticancer drugs to treat various cancers, such as leukemia, prostate, lung, stomach, intestine, kidney and melanoma. The Company also offers polymer-antibiotics targeted for human use. The Company's Recce antibiotic kills all types of bacteria, including superbugs. Its subsidiaries include Recce (USA) LLP and Recce (UK) Limited.
Home Page: www.recce.com.au
RCE Technical Analysis
Aurora Place
Sydney,
NSW
2000
Australia
Phone:
61 2 9256 2571
Officers
| Name | Title |
|---|---|
| Mr. James Hamilton-Bray Graham GAICD | CEO, MD & Exec. Director |
| Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci) | Chief Scientific Director & Exec. Director |
| Dr. Justin Ward | Principal Quality Chemist & Exec. Director |
| Mr. Arthur Kollaras | Principal Engineer & Head of Manufacturing |
| Mr. Justin Reynolds | Chief Financial Officer |
| Thomas Jarrett | Operations Mang. |
| Mr. Daniel Astudillo B.A., B.Com., M.B.A. | Head of Marketing |
| Ms. Maggie Niewidok | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 11.7701 |
| Price-to-Sales TTM: | 38.0985 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |